PARP1 and prostate neoplasm: We believe that it is mandatory to extend the analysis of CCDC6 and USP7 protein expression to a larger series of prostate tumor samples in order to strenghten our observations about the joined/combined expression of the two proteins, and to predict the outcome of this tumor following the treatment with the USP7 inhibitors and PARP inhibitors, in combination with genotoxic durgs.